

# Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

## Mino

RRID:CVCL\_1872

Type: Cell Line

### Proper Citation

RRID:CVCL\_1872

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1872](https://web.expasy.org/cellosaurus/CVCL_1872)

**Proper Citation:** RRID:CVCL\_1872

**Description:** Cell line Mino is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Mantle cell lymphoma

**Defining Citation:** [PMID:12127561](#), [PMID:12683869](#), [PMID:21746927](#), [PMID:22460905](#), [PMID:24362935](#), [PMID:25315077](#), [PMID:25355872](#), [PMID:25688540](#), [PMID:25960936](#), [PMID:26194763](#), [PMID:28196595](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#)

**Comments:** Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank)., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** Mino

**Synonyms:** MINO

**Cross References:** EFO:EFO\_0022501, AddexBio:C0003033/4947, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-3000, BioSample:SAMN03471705, BioSample:SAMN10988480, cancercellines:CVCL\_1872, Cell\_Model\_Passport:SIDM01667, ChEMBL-Cells:ChEMBL4523520, ChEMBL-Targets:ChEMBL4523551, CLS:305513,

Cosmic:2078181, Cosmic:2088019, Cosmic:2756236, DepMap:ACH-000220, DSMZ:ACC-687, DSMZCellDive:ACC-687, GEO:GSM629496, GEO:GSM629497, GEO:GSM887321, GEO:GSM888397, GEO:GSM907522, GEO:GSM1044970, GEO:GSM1044971, GEO:GSM1044972, GEO:GSM1044973, GEO:GSM1670110, GEO:GSM2322625, IARC\_TP53:17152, LiGeA:CCLE\_916, Lonza:165, PharmacDB:Mino\_932\_2019, Progenetix:CVCL\_1872, PubChem\_Cell\_line:CVCL\_1872, Wikidata:Q54905748

**ID:** CVCL\_1872

**Record Creation Time:** 20220427T220809+0000

**Record Last Update:** 20260905T181147+0000

---

## Ratings and Alerts

No rating or validation information has been found for Mino.

No alerts have been found for Mino.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Roleder C, et al. (2026) Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. Cancer research communications, 6(5), 1192.

Dell'Aversana C, et al. (2026) UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. Journal of hematology & oncology, 19(1).

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. The Journal of pharmacology and experimental therapeutics, 392(8), 103634.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Donovan KA, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degradation Development. *Cell*, 183(6), 1714.

Marchesini M, et al. (2020) Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. *Cell chemical biology*, 27(6), 678.

Perrot I, et al. (2019) Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. *Cell reports*, 27(8), 2411.

Steinberger J, et al. (2019) Tracing MYC Expression for Small Molecule Discovery. *Cell chemical biology*, 26(5), 699.